losartan has been researched along with s 1033 in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 2 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Delabio, LC; Dutra, JP; Hembecker, M; Kita, DH; Moure, VR; Pereira, GDS; Scheiffer, G; Valdameri, G; Zattoni, IF | 1 |
| Bahabadi, M; Goudarzi, F; Hajilooi, M; Hashemnia, M; Hedayatyanfard, K; Karimi, J; Khanjarsim, V; Kheiripour, N; Khodadadi, I; Mohammadalipour, A; Sheikh, N; Solgi, G | 1 |
2 review(s) available for losartan and s 1033
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Targeting breast cancer resistance protein (BCRP/ABCG2): Functional inhibitors and expression modulators.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; Breast Neoplasms; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Neoplasm Proteins; Neoplastic Stem Cells | 2022 |
1 other study(ies) available for losartan and s 1033
| Article | Year |
|---|---|
Protective effects of combined Losartan and Nilotinib on carbon tetrachloride (CCl
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Carbon Tetrachloride; Drug Therapy, Combination; Liver Cirrhosis; Losartan; Male; Oxidative Stress; Protein-Tyrosine Kinases; Pyrimidines; Rats; Rats, Wistar; Transforming Growth Factor beta1; Weight Gain | 2020 |